Investigational drug · Phase 2
certepetide
Also called: CEND-1, LSTA1
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
7
Any phase or sponsor naming "certepetide"
First trial start
2023
May 13, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "certepetide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cholangiocarcinoma
- Gallbladder Cancer
- Gallbladder Carcinoma
- Intrahepatic Cholangiocarcinoma
- Extrahepatic Cholangiocarcinoma
- Bile Duct Cancer
- Gall Bladder Cancer
- Gall Bladder Carcinoma
Approved drugs for the same conditions: Bladder and urothelial cancer · Oncology · Kidney and urology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "certepetide" as an intervention, largest first.
- The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal AdenocarcinomaPivotal-lookingStatus unknown
Australasian Gastro-Intestinal Trials GroupResearch network
NCT05042128 · 158 participants · Start Apr 13, 2022 · Primary completion Jun 1, 2025
Drug: LSTA1; Gemcitabine Injection and 1 more · For: Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Cancer
Sites: Albury, Australia; Camperdown, Australia; Clayton, Australia · 24 sites in all
- A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal AdenocarcinomaPivotal-lookingStatus unknown
Qilu Pharmaceutical Co., Ltd.Industry
NCT06261359 · 120 participants (planned) · Start Mar 19, 2024 · Primary completion Apr 2025
Drug: CEND-1; Gemcitabine and 1 more · For: Pancreatic Ductal Adenocarcinoma (PDAC)
Sites: Beijing, China
Lisata Therapeutics, Inc.Industry
NCT05712356 · 66 participants · Start May 13, 2023 · Primary completion Apr 5, 2026
Drug: certepetide; Durvalumab and 4 more · For: Cholangiocarcinoma; Gallbladder Cancer; Gallbladder Carcinoma and 5 more
Sites: Gilbert, Arizona; Phoenix, Arizona; Tucson, Arizona · 19 sites in all
Anup KasiAcademic, hospital or other
NCT05121038 · 50 participants (planned) · Start Oct 20, 2021 · Primary completion Sep 2025
Drug: CEND-1; Panitumumab and 1 more · For: Colon Cancer; Pancreas Cancer; Digestive Cancer
Sites: Fairway, Kansas; Kansas City, Kansas; North Kansas City, Missouri
- CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal AdenocarcinomaCompleted
Qilu Pharmaceutical Co., Ltd.Industry
NCT05052567 · 50 participants · Start Oct 21, 2021 · Primary completion Jun 29, 2024
Drug: CEND-1 · For: Pancreatic Cancer
Sites: Beijing, China
Lisata Therapeutics, Inc.Industry
NCT03517176 · 30 participants · Start Jul 31, 2018 · Primary completion Jun 19, 2020
Drug: CEND-1; Nab-paclitaxel and 1 more · For: Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma
Sites: Woodville South, Australia; Melbourne, Australia; Subiaco, Australia
Lisata Therapeutics, Inc.Industry
NCT06592664 · 0 participants · Start Jan 2030 · Primary completion Jan 2035
Drug: certepetide; nab-paclitaxel and 5 more · For: Pancreas Cancer; Pancreatic Carcinoma; Pancreas Adenocarcinoma and 5 more
Newest research
PubMed records naming it or its code names, newest first.
- Tumor-homing peptides in precision oncology.
Ma G, Derkaoui DK, Senhadji R, et al. · J Control Release 2026
- Anticancer Peptides: Design Principles, Translational Bottlenecks, and Emerging Opportunities.
Di ME, Di YP · Molecules 2026
- Targeting the neuropilin 1/interferon γ axis restores glucocorticoid-suppressed T cell function and rescues bone formation to prevent steroid-induced osteonecrosis.
Lu H, Chen B, Cheng C, et al. · Bone Joint Res 2026
- [68Ga]Ga-DOTA-CEND1: A Novel PET Cyclic Peptide Tracer for Noninvasive Imaging of Neuropilin-1 Expression in Pan-Tumors.
Qiu F, Tang S, Liu X, et al. · Mol Pharm 2026
- LSTA1-GBM-2A: study protocol for an exploratory phase 2a randomised controlled trial evaluating tumour-homing peptide certepetide with temozolomide in glioblastoma multiforme.
Truusalu JP, Oselin K, Lass J, et al. · BMJ Open 2025
- Population Pharmacokinetic Modeling of Certepetide in Human Subjects With Metastatic Pancreatic Ductal Adenocarcinoma.
Winning A, Sietsema WK, Buck KK, et al. · Clin Pharmacol Drug Dev 2025
Also in development for Cholangiocarcinoma
- tinengotinibTT-00420Phase 36 trials
TransThera Sciences (Nanjing), Inc. · Prostate Cancer (CRPC), Cholangiocarcinoma, Hepatocellular Carcinoma (HCC)
- [18F]FAPI-74 PETPhase 33 trials
SOFIE · Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction
- CTX-009Phase 32 trials
Compass Therapeutics · Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer
- GV20-0251Phase 23 trials
GV20 Therapeutics · Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, pMMR/MSS Adenocarcinoma of the Colon or Rectum
- CGT4859Phase 21 trial
Cogent Biosciences, Inc. · Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult
- E7090Phase 21 trial
Eisai · Cholangiocarcinoma
- gavo-celPhase 21 trial
TCR2 Therapeutics · Mesothelioma, Mesothelioma, Malignant, Mesothelioma; Pleura
- GNS561Phase 21 trial
Genfit · Cholangiocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.